Celgene Corp (NASDAQ:CELG)

CAPS Rating: 4 out of 5

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.

Recs

0
Player Avatar mizan1030 (< 20) Submitted: 2/17/2013 3:18:19 PM : Outperform Start Price: $49.49 CELG Score: +9.76

Well-managed management team. Company's new cancer drug is making company tons of money and will continue to do so for a long, long time. Combine a good management and a quality product that consumers are buying, we've got a great company. This is one of those.

Featured Broker Partners


Advertisement